Locations
San Jose, CA, USA · Menlo Park, CA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series C+
founded in
2017
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Their proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site over weeks, significantly exceeding the duration of existing pain treatments. The lead product, ATX101, is designed to provide weeks of pain relief following total knee arthroplasty (TKA) and is currently in Phase 2 clinical trials. Allay aims to address the opioid crisis by offering a non-opioid solution that reduces reliance on opioids and enhances recovery outcomes for patients. The company operates with a global team of experts in the San Francisco Bay Area and Singapore, focusing on innovative pain management solutions.
Something looks off?